- Home
- GPN vs ROIV Comparison
GPN vs ROIV Comparison
Compare GPN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPN | ROIV |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8B | 20.7B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GPN | ROIV |
|---|---|---|
| Price | $68.61 | $29.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $92.50 | $27.56 |
| AVG Volume (30 Days) | 3.0M | ★ 4.1M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.78 | N/A |
| Revenue | ★ $3,975,163,000.00 | $29,053,000.00 |
| Revenue This Year | $64.54 | N/A |
| Revenue Next Year | $6.22 | $878.32 |
| P/E Ratio | $11.79 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $62.45 | $9.90 |
| 52 Week High | $90.64 | $30.33 |
Technical Indicators
Market Signals| Indicator | GPN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 60.69 |
| Support Level | $67.26 | $20.46 |
| Resistance Level | $81.95 | $30.33 |
| Average True Range (ATR) | 2.86 | 0.92 |
| MACD | 0.40 | 0.11 |
| Stochastic Oscillator | 57.20 | 84.62 |
Price Performance
Historical ComparisonAbout GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.